7 results
10-K
2021 FY
LYEL
Lyell Immunopharma, Inc.
29 Mar 22
Annual report
4:20pm
adversely impact the timing of the commercial launch of the product.
In 2017, the FDA established a new regenerative medicine advanced therapy (RMAT
424B4
LYEL
Lyell Immunopharma, Inc.
18 Jun 21
Prospectus supplement with pricing info
12:00am
the timing of the commercial launch of the product.
In 2017, the FDA established a new regenerative medicine advanced therapy (RMAT) designation, which
S-1/A
LYEL
Lyell Immunopharma, Inc.
9 Jun 21
IPO registration (amended)
7:12am
regenerative medicine advanced therapy (RMAT) designation, which is intended to facilitate an efficient development program for, and expedite review
S-1
LYEL
Lyell Immunopharma, Inc.
25 May 21
IPO registration
5:28pm
regenerative medicine advanced therapy (RMAT) designation, which is intended to facilitate an efficient development program for, and expedite review of, any
DRS/A
l3u3 4f84c
12 May 21
Draft registration statement (amended)
12:00am
DRS
oxn0 z7p2jz4ppl6b
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next